Adocia SA (ADOC.PA)
EUR 6.39
(1.59%)
EUR 6.39
(1.59%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 31.87 Million EUR | -26.88% |
| 2022 | 43.58 Million EUR | -0.65% |
| 2021 | 43.86 Million EUR | 12.97% |
| 2020 | 38.83 Million EUR | 14.5% |
| 2019 | 33.91 Million EUR | 40.17% |
| 2018 | 24.19 Million EUR | 43.13% |
| 2017 | 16.9 Million EUR | -53.09% |
| 2016 | 36.03 Million EUR | -12.2% |
| 2015 | 41.04 Million EUR | -17.98% |
| 2014 | 50.03 Million EUR | 793.71% |
| 2013 | 5.59 Million EUR | -58.83% |
| 2012 | 13.59 Million EUR | 2.2% |
| 2011 | 13.3 Million EUR | 204.07% |
| 2010 | 4.37 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 31.35 Million EUR | 0.0% |
| 2023 Q3 | 31.87 Million EUR | -19.18% |
| 2023 Q4 | 31.87 Million EUR | 0.0% |
| 2023 Q1 | 39.43 Million EUR | -9.52% |
| 2023 FY | 31.87 Million EUR | -26.88% |
| 2023 Q2 | 39.43 Million EUR | 0.0% |
| 2022 FY | 43.58 Million EUR | -0.65% |
| 2022 Q3 | 43.58 Million EUR | -5.65% |
| 2022 Q4 | 43.58 Million EUR | 0.0% |
| 2022 Q2 | 46.19 Million EUR | 0.0% |
| 2022 Q1 | 46.19 Million EUR | 5.29% |
| 2021 Q3 | 43.86 Million EUR | 15.64% |
| 2021 Q4 | 43.86 Million EUR | 0.0% |
| 2021 Q1 | 37.93 Million EUR | -2.3% |
| 2021 FY | 43.86 Million EUR | 12.97% |
| 2021 Q2 | 37.93 Million EUR | 0.0% |
| 2020 Q2 | 33.73 Million EUR | 0.0% |
| 2020 Q1 | 33.73 Million EUR | -0.54% |
| 2020 Q3 | 38.83 Million EUR | 15.13% |
| 2020 Q4 | 38.83 Million EUR | 0.0% |
| 2020 FY | 38.83 Million EUR | 14.5% |
| 2019 Q2 | 22.89 Million EUR | 0.0% |
| 2019 Q4 | 33.91 Million EUR | 0.0% |
| 2019 FY | 33.91 Million EUR | 40.17% |
| 2019 Q1 | 22.89 Million EUR | -5.36% |
| 2019 Q3 | 33.91 Million EUR | 48.1% |
| 2018 Q3 | 24.19 Million EUR | -28.51% |
| 2018 FY | 24.19 Million EUR | 43.13% |
| 2018 Q4 | 24.19 Million EUR | 0.0% |
| 2018 Q2 | 33.84 Million EUR | 0.0% |
| 2018 Q1 | 33.84 Million EUR | 100.21% |
| 2017 Q1 | 17.3 Million EUR | -51.97% |
| 2017 Q2 | 17.3 Million EUR | 0.0% |
| 2017 Q3 | 16.9 Million EUR | -2.34% |
| 2017 Q4 | 16.9 Million EUR | 0.0% |
| 2017 FY | 16.9 Million EUR | -53.09% |
| 2016 Q2 | 42.1 Million EUR | 0.0% |
| 2016 FY | 36.03 Million EUR | -12.2% |
| 2016 Q1 | 42.1 Million EUR | 2.59% |
| 2016 Q3 | 36.03 Million EUR | -14.41% |
| 2016 Q4 | 36.03 Million EUR | 0.0% |
| 2015 Q3 | 41.04 Million EUR | -4.21% |
| 2015 Q2 | 42.84 Million EUR | 0.0% |
| 2015 FY | 41.04 Million EUR | -17.98% |
| 2015 Q1 | 42.84 Million EUR | -14.37% |
| 2015 Q4 | 41.04 Million EUR | 0.0% |
| 2014 Q2 | 5.96 Million EUR | 0.0% |
| 2014 Q3 | 50.03 Million EUR | 739.02% |
| 2014 Q4 | 50.03 Million EUR | 0.0% |
| 2014 Q1 | 5.96 Million EUR | 6.52% |
| 2014 FY | 50.03 Million EUR | 793.71% |
| 2013 Q1 | 11.52 Million EUR | -15.25% |
| 2013 Q4 | 5.59 Million EUR | 0.0% |
| 2013 Q2 | 11.52 Million EUR | 0.0% |
| 2013 Q3 | 5.59 Million EUR | -51.42% |
| 2013 FY | 5.59 Million EUR | -58.83% |
| 2012 Q3 | 13.59 Million EUR | 4.74% |
| 2012 Q4 | 13.59 Million EUR | 0.0% |
| 2012 FY | 13.59 Million EUR | 2.2% |
| 2012 Q2 | 12.98 Million EUR | 0.0% |
| 2011 FY | 13.3 Million EUR | 204.07% |
| 2011 Q4 | 13.3 Million EUR | 0.0% |
| 2010 FY | 4.37 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -361.082% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 75.681% |
| Aelis Farma SA | 13.08 Million EUR | -143.654% |
| Biophytis S.A. | 15.84 Million EUR | -101.085% |
| Advicenne S.A. | 24.37 Million EUR | -30.738% |
| genOway Société anonyme | 14.45 Million EUR | -120.409% |
| IntegraGen SA | 5.97 Million EUR | -432.961% |
| Medesis Pharma S.A. | 6.42 Million EUR | -395.94% |
| Neovacs S.A. | 3.71 Million EUR | -758.538% |
| NFL Biosciences SA | 3.62 Million EUR | -780.221% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -369.896% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -862.809% |
| Sensorion SA | 13.22 Million EUR | -140.942% |
| Theranexus Société Anonyme | 5.01 Million EUR | -535.343% |
| TME Pharma N.V. | 2.78 Million EUR | -1044.345% |
| Valbiotis SA | 13.7 Million EUR | -132.492% |
| TheraVet SA | 1.48 Million EUR | -2046.138% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -55.706% |
| argenx SE | 402.79 Million EUR | 92.088% |
| BioSenic S.A. | 32.26 Million EUR | 1.221% |
| Celyad Oncology SA | 9.97 Million EUR | -219.403% |
| DBV Technologies S.A. | 38.74 Million USD | 17.745% |
| Galapagos NV | 1.56 Billion EUR | 97.959% |
| Genfit S.A. | 105.92 Million EUR | 69.912% |
| GeNeuro SA | 20.13 Million EUR | -58.243% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -270.065% |
| Innate Pharma S.A. | 132.29 Million EUR | 75.909% |
| Inventiva S.A. | 101.59 Million EUR | 68.63% |
| MaaT Pharma SA | 22.46 Million EUR | -41.865% |
| MedinCell S.A. | 77.77 Million EUR | 59.02% |
| Nanobiotix S.A. | 95.74 Million EUR | 66.712% |
| Onward Medical N.V. | 25.69 Million EUR | -24.017% |
| Oryzon Genomics S.A. | 25.12 Million EUR | -26.843% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 46.055% |
| Oxurion NV | 19.73 Million EUR | -61.482% |
| Pharming Group N.V. | 228.28 Million EUR | 86.039% |
| Poxel S.A. | 53.9 Million EUR | 40.873% |
| GenSight Biologics S.A. | 34.72 Million EUR | 8.227% |
| Transgene SA | 26.51 Million EUR | -20.187% |
| Financière de Tubize SA | 123.65 Million EUR | 74.226% |
| UCB SA | 6.56 Billion EUR | 99.514% |
| Valneva SE | 341.14 Million EUR | 90.658% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -600.902% |